Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
New England Journal of MedicinePublished 20 September 2001Open access
Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke, Tomás Berl, Marc A. Pohl, Julia B. Lewis
Citations5,920
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Abstract
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes.
Keywords
Medicine
New England Journal of MedicineEffects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
8,611 Citations2000Salim Yusuf
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure in a two-by-two factorial study evaluating ramipril and vitamin E.
The LancetEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
5,765 Citations1998Lennart Hansson, Alberto Zanchetti +8 more
Intensive lowering of blood pressure in patients with hypertension was associated with a low rate of cardiovascular events and the potential benefit of a low dose of acetylsalicylic acid in the treatment of hypertension was assessed.
New England Journal of MedicineThe Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
5,377 Citations1993Edmund J. Lewis, Lawrence G. Hunsicker +2 more
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
The LancetEffects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
1,782 Citations2000Blood Pressure Lowering Treatment Trialists' Collaboration
Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials, and data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.
BiometrikaDiscrete sequential boundaries for clinical trials
1,740 Citations1983K. K. Gordon Lan, David L. DeMets
A more flexible way to construct discrete sequential boundaries is proposed, based on the choice of a function, a*(t), which characterizes the rate at which the error level ac is spent.
The LancetRandomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
1,443 Citations1999Lennart Hansson, Lars Lindholm +7 more
Old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events, and decrease in blood pressure was of major importance for the Prevention of cardiovascular events.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
1,408 Citations1998M R Stearne, S L Palmer +261 more
BMJEfficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
1,390 Citations1998UK Prospective Diabetes Study Group,
This study provided no evidence that either drug has any specific beneficial or deleterious effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.
Journal of Clinical InvestigationPrevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
1,213 Citations1986Roberto Zatz, B R Dunn +4 more
Prevention of glomerular capillary hypertension in rats with diabetes mellitus effectively protects against the subsequent development ofglomerular structural injury and proteinuria, further supporting the view that hemodynamic rather than metabolic factors predominate in the pathogenesis of diabetic glomerulopathy.
Journal of Clinical InvestigationAngiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.
1,076 Citations1994Shoji Kagami, Wayne A. Border +2 more
Results indicate that Ang II induces mesangial cell synthesis of matrix proteins and show that these effects are mediated by Ang II induction of TGF-beta expression, which may well contribute to glomerulosclerosis in vivo.
Diabetes CareDiabetes trends in the U.S.: 1990-1998.
1,044 Citations2000Ali H. Mokdad, Earl S. Ford +5 more
The prevalence of diabetes continues to increase rapidly in the U.S. and will become even more common because the prevalence of obesity is also rising, and major efforts are needed to alter these trends.
New England Journal of MedicineEffects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension
946 Citations1999Jaakko Tuomilehto, Daiva Rastenytė +11 more
Antihypertensive treatment with the calcium-channel blocker nitrendipine reduced the risk of cardiovascular events in diabetic and nondiabetic patients and was compared with placebo in this post hoc analysis.
Annals of Internal MedicineLong-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients
784 Citations1993Mordchai Ravid, Hilel Savin +4 more
A relatively long-term, 5-year study of the effect of the angiotensin-converting enzyme inhibitor, enalapril, on the course of diabetic nephropathy in normotensive, type II diabetic patients with microalbuminuria and normal renal function.
TechnometricsStatistical Methods for the Analysis of Biomedical Data
584 Citations1989Eric Ziegel, Robert F. Woolson
PubMedAngiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells.
336 Citations1992Günter Wolf, Uwe Haberstroh +1 more
It is indicated collectively that ANG II in serum-free cultures can be a paracrine catalyst for the growth and biosynthesis of type I collagen in mesangial cells.
Journal of the American Society of NephrologyThe Paradox of the Low-Renin State in Diabetic Nephropathy
272 Citations1999Deborah A. Price, Lisa E. Porter +7 more
It is proposed that there is increased intrarenal AngII production in type 2 diabetes mellitus, which could account for suppressed circulating renin, the exaggerated renal vasodilator response to irbesartan, and the therapeutic effectiveness of interrupting the renin system in diabetic nephropathy.
Journal of the American Society of NephrologyIn progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation.
245 Citations1998Mauro Abbate, Carla Zoja +4 more
This study analyzes the time course and sites of protein accumulation and interstitial cellular infiltration in two different models of proteinuric nephropathies, indicating that the interstitial inflammatory reaction develops at the sites ofprotein overload, regardless of the type of glomerular injury.
Kidney InternationalBradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
201 Citations1993Valentina Kon, Agnes B. Fogo +3 more
The effects of interruption of the renin-angiotensin system in rats that were volume depleted by water deprivation for 48 hours (AWD) with/without furosemide were studied to examine effects of a specific bradykinin antagonist (Hoe).
American Journal of Kidney DiseasesChronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
175 Citations2000Piero Ruggenenti, Annalisa Perna +3 more
The Ramipril Efficacy in Nephropathy study found that angiotensin-converting enzyme (ACE) inhibitors effectively decreased proteinuria, glomerular filtration rate (GFR) decline (DeltaGFR), and incidence of end-stage renal disease (ESRD) in patients with proteinuric chronic nephropathies.
Nephrology Dialysis TransplantationThe Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
129 Citations2000Roger A. Rodby, Richard D. Rohde +6 more
The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), studying the effect of the angiotensin II receptor antagonist irbesarta on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension.
HypertensionRenal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy Men
57 Citations1997Deborah A. Price, JOSE MARIO F. DE'OLIVEIRA +2 more
The renal vasodilator response to the angiotensin II antagonist eprosartan closely resembles responses to renin inhibition and exceeds previously reported responses to ACE inhibitors.
Kidney InternationalGlomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade
53 Citations1999Piero Ruggenenti, Lidia Mosconi +5 more
It is indicated that patients with NIDDM and overt nephropathy develop abnormalities in size-selective function of the glomerular barrier and, at variance to IDDM, such changes were not ameliorated either by ACE inhibition or calcium channel blockade.
HypertensionEffect of Angiotensin II Antagonist Eprosartan on Hyperglycemia-Induced Activation of Intrarenal Renin-Angiotensin System in Healthy Humans
47 Citations2000Suzette Y. Osei, Deborah A. Price +3 more
The enhancement of the renal vasodilator effect of eprosartan during hyperglycemia is consistent with activation of the intrarenal renin-angiotensin system.